TRAX
NASDAQFirst Tracks Biotherapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$15.77-0.75 (-4.51%)
01:30 PM07:45 PM
News · 26 weeks41-95%
2025-12-142026-06-07
Mix4190d
- Insider24(59%)
- Analyst8(20%)
- SEC Filings6(15%)
- Other3(7%)
Latest news
25 items- ANALYSTWells Fargo initiated coverage on First Tracks Biotherapeutics with a new price targetWells Fargo initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $30.00
- PRFirst Tracks Biotherapeutics Announces Participation in Upcoming Investor ConferencesSAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: 2026 Jefferies Global Healthcare Conference, New York Format – Presentation and one-on-one investor meetingsDate and Time – Wednesday, June 3, 2026 at 12:15pm ET / 9:15am PT Leerink Partners Therapeutics Forum, Boston Format – One-on-one i
- SECSEC Form 424B3 filed by First Tracks Biotherapeutics Inc.424B3 - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECSEC Form 424B3 filed by First Tracks Biotherapeutics Inc.424B3 - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECSEC Form 10-Q filed by First Tracks Biotherapeutics Inc.10-Q - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECFirst Tracks Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- PRFirst Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateFirst Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. "First Tracks Bio launched to advance a focused, high-value immunology portfolio that can create meaningful impact and a future where
- INSIDERSEC Form 4 filed by Director Jain Rita4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Director Ware J. Anthony4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Director Schmid John P.4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Director Marquet Magda4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Director Fenton Dennis M4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Stone Benjamin4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Director Orwin John A4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Tamboli Ajim4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO Faga Daniel4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Lizzul Paul F.4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- SECSEC Form EFFECT filed by First Tracks Biotherapeutics Inc.EFFECT - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECSEC Form S-1 filed by First Tracks Biotherapeutics Inc.S-1 - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- ANALYSTPiper Sandler initiated coverage on First Tracks Biotherapeutics with a new price targetPiper Sandler initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $54.00
- ANALYSTH.C. Wainwright initiated coverage on First Tracks Biotherapeutics with a new price targetH.C. Wainwright initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $30.00
- ANALYSTWedbush initiated coverage on First Tracks Biotherapeutics with a new price targetWedbush initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $30.00
- ANALYSTLeerink Partners initiated coverage on First Tracks Biotherapeutics with a new price targetLeerink Partners initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $46.00
- INSIDERSEC Form 3 filed by new insider Tamboli Ajim3 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Tamboli Ajim4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
TRAX FAQ
5 questionsWhere does TRAX stock trade?
First Tracks Biotherapeutics Inc. (TRAX) is listed on NASDAQ.What sector and industry is TRAX in?
First Tracks Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TRAX?
First Tracks Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $3000.00 price target on 2026-06-08. Recent price targets range from $3000.00 to $4600.00.What companies are similar to TRAX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TRAX side-by-side with any of them on Quantisnow.How can I track TRAX on Quantisnow?
Quantisnow aggregates First Tracks Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRAX to receive live email and push alerts on every new disclosure.